Novo Nordisk's Deal Spree: Expanding Drug Pipeline

Novo Nordisks CEO, Mike Doustdar, reveals the companys aggressive strategy to acquire and partner for a diverse drug pipeline, targeting treatments for hundreds of millions of patients. Novo aims to secure assets that complement their existing portfolio, with more deals and collaborations on the horizon. Despite Eli Lillys lead in weekly GLP-one injections, Novo maintains an edge in the GLP-one pill market for weight loss. Novos recent success with their Wegovy pill has boosted their confidence, leading to an increased full-year profit forecast. As the weight-loss drug race intensifies, Novo is expanding its reach through strategic moves. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/86333de2745e9cb3